PubRank

Safety Study of Nivolumab by Itself or in Combination in Patients With Lymphoma or Multiple Myeloma

Clinical Trial ID NCT01592370

PubWeight™ 44.33‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01592370

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2014 10.10
2 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
3 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
4 A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015 1.57
5 The role of B7 family molecules in hematologic malignancy. Blood 2012 1.47
6 Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013 1.41
7 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
8 Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol 2016 1.17
9 Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 2015 1.09
10 Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016 1.06
11 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
12 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
13 Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol 2015 0.92
14 Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia 2015 0.92
15 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
16 Novel immunotherapies for hematologic malignancies. Immunol Rev 2015 0.90
17 Promising therapies in multiple myeloma. Blood 2015 0.89
18 Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant 2015 0.89
19 Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016 0.89
20 Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta 2015 0.86
21 The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015 0.85
22 Customized targeted therapy in Hodgkin lymphoma: hype or hope? Hematol Oncol Clin North Am 2014 0.82
23 New strategies in Hodgkin lymphoma: better risk profiling and novel treatments. Clin Cancer Res 2013 0.81
24 The development of potential antibody-based therapies for myeloma. Blood Rev 2014 0.81
25 Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin Biol Ther 2015 0.79
26 Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma. J Cell Biochem 2016 0.78
27 Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology 2015 0.78
28 Immunotherapeutic approaches to treat multiple myeloma. Hum Vaccin Immunother 2013 0.77
29 The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals (Basel) 2016 0.77
30 Relapsed Hodgkin lymphoma: management strategies. Curr Hematol Malig Rep 2014 0.76
31 Antibody therapy of pediatric B-cell lymphoma. Front Oncol 2013 0.75
32 Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. BMC Infect Dis 2016 0.75
33 Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther 2016 0.75
34 Recent advances in the management of Hodgkin lymphoma. F1000Res 2016 0.75
35 Novel Drugs in Follicular Lymphoma. Mediterr J Hematol Infect Dis 2016 0.75
36 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
37 Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. J Mol Med (Berl) 2015 0.75
Next 100